B Group Inc. Grows Holdings in Sight Sciences, Inc. $SGHT

B Group Inc. grew its stake in Sight Sciences, Inc. (NASDAQ:SGHT) by 11.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 930,000 shares of the company’s stock after purchasing an additional 96,400 shares during the quarter. Sight Sciences comprises about 3.0% of B Group Inc.’s holdings, making the stock its 8th biggest holding. B Group Inc.’s holdings in Sight Sciences were worth $3,841,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the stock. Nuveen LLC purchased a new position in shares of Sight Sciences in the 1st quarter valued at approximately $154,000. Long Focus Capital Management LLC raised its holdings in Sight Sciences by 39.7% in the first quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company’s stock worth $7,504,000 after purchasing an additional 887,876 shares in the last quarter. AQR Capital Management LLC purchased a new position in Sight Sciences during the first quarter valued at $128,000. Acadian Asset Management LLC boosted its holdings in shares of Sight Sciences by 127.7% during the 1st quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock valued at $1,033,000 after buying an additional 242,559 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of Sight Sciences in the 1st quarter worth about $158,000. Institutional investors own 55.51% of the company’s stock.

Insider Transactions at Sight Sciences

In other Sight Sciences news, CEO Paul Badawi sold 24,441 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $3.34, for a total value of $81,632.94. Following the transaction, the chief executive officer owned 5,962,502 shares of the company’s stock, valued at approximately $19,914,756.68. This represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeremy B. Hayden sold 44,850 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $8.08, for a total value of $362,388.00. Following the completion of the transaction, the insider directly owned 256,590 shares in the company, valued at $2,073,247.20. The trade was a 14.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 103,214 shares of company stock worth $624,583 in the last ninety days. Insiders own 28.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wall Street Zen raised shares of Sight Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Citigroup cut their target price on Sight Sciences from $4.50 to $4.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 7th. Piper Sandler lifted their price target on Sight Sciences from $4.00 to $5.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Thursday, August 28th. Finally, Lake Street Capital raised their price objective on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sight Sciences currently has an average rating of “Hold” and a consensus target price of $5.50.

Sight Sciences Trading Up 6.0%

Sight Sciences stock opened at $8.53 on Tuesday. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $8.80. The business’s fifty day moving average is $5.73 and its 200 day moving average is $4.49. The stock has a market capitalization of $450.98 million, a PE ratio of -9.48 and a beta of 2.41. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The business had revenue of $12.54 million during the quarter. On average, sell-side analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current year.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.